JPRN-UMIN000002968已完成未知
Global Clinical Study on Ethnic Differences in Drug Metabolism Based on the Joint Statement by the Japanese, Chinese and Korean Ministers of Health: Clinical Pharmacokinetic Study of Moxifloxacin in Healthy Adult Male Subjects. - Comparative Pharmacokinetic Study of Moxifloxacin among Japan, Korea, China, and USA.
Research Group of Global Clinical Study on Ethnic Differences in Drug Metabolism Based on the Announcement by the Japanese, Chinese and Korean Ministers of Health, Labor and Welfare0 个研究点目标入组 80 人开始时间: 2010年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 35years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1) Organopathy involving the heart (QTc prolongation* etc.), lung, liver and/or kidney, etc., and hypokalemia. 2) A history of diseases involving the heart, lung, kidney, blood (such as coagulation system disorder), central nervous system, metabolic system and skeletal muscle system that may interfere with the study. 3) Hypersensitivity or allergies to drugs, food, etc. (Particularly, a history of allergy to or adverse reactions associated with quinolone antibacterials) 4) Oral administration of drugs such as over-the-counter drugs, supplements or health foods within 1 week prior to the study drug administration, or the necessity for using other medications before study completion. 5) Smokers or a smoking history within the last 6 months. (The cotinine test is performed, if necessary) 6) Drug abuse or suspicion of drug abuse (The drug screening test is performed, if necessary) 7) Alcohol drinkers (daily alcohol intake* of 50 g or more). 8) Total bilirubin or direct bilirubin is 1.5 times higher and other liver function tests items are 1.25 times higher than the upper limits of normal at the sites. 9) Transfusion of 200 mL or more within 1 month prior to study drug administration, blood component donation (plasma or platelet) within 2 weeks, or blood collection of 400 mL or more within 3 months. 10) Participation in a Phase I study of a drug containing a new active ingredient within 4 months prior to study drug administration or another clinical study within 3 months, and being administered the investigational drug (within 1 month prior to study drug administration for a patch test). However, even if the period is longer than these, those who are determined to be not eligible for enrollment in the study in consideration of the characteristics of the previous investigational drug. 11) Those who are determined by the investigator to be not suitable as subjects of the study.
研究者
相似试验
已完成
不适用
Global Clinical Study on Ethnic Differences in Drug Metabolism Based on the Joint Statement by the Japanese, Chinese and Korean Ministers of Health: Clinical Pharmacokinetic Study of Meloxicam in Healthy Adult Male SubjectsHealthy adult male subjectsJPRN-UMIN000004173Research Group of Global Clinical Study on Ethnic Differences in Drug Metabolism Based on the Announcement by the Japanese, Chinese and Korean Ministers of Health, Labor and Welfare120
已完成
不适用
Global Clinical Study on Ethnic Differences in Drug Metabolism Based on the Joint Statement by the Japanese, Chinese and Korean Ministers of Health: Clinical Pharmacokinetic Study of Simvastatin in Healthy Adult Male Subjects.Healthy adult male subjectsJPRN-UMIN000003644Research Group of Global Clinical Study on Ethnic Differences in Drug Metabolism Based on the Announcement by the Japanese, Chinese and Korean Ministers of Health, Labor and Welfare160
进行中（未招募）
Unknown
Effectiveness of a food supplement on hair lossAcute telogen effluvium from less than 6 months (presenting =15% of telogen parameter at inclusion), with a hair length of at least 5 cm, complaining of brittle and thin hairSkin and Connective Tissue DiseasesISRCTN12522754ROELMI HPC Srl60
尚未招募
2 期
Daruharidra madhu kwath aschyotana and triphala kwath aschyotana in vataj abhishadhaCTRI/2022/12/048002Dr Snehal Sampatrao Pakhare
已完成
不适用
*Interculturalisation: Diagnostic Evaluation with Ethnic minority patients with Low back disabilities* (IDEAL)NL-OMON30507JBI - Instituut voor Reumatologie en Revalidatie35